APA (7th ed.) Citation

J, T., R, W., M, N., JML, E., T, I., M, S., . . . K, T. (2026). TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer. Annals of surgical oncology, 33(4), 3263. https://doi.org/10.1245/s10434-025-18764-x

Chicago Style (17th ed.) Citation

J, Tsuchida, Wu R, Nagahashi M, Ebos JML, Ishikawa T, Shimoda M, Wakai T, and Takabe K. "TRIM37 Expression Is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer." Annals of Surgical Oncology 33, no. 4 (2026): 3263. https://doi.org/10.1245/s10434-025-18764-x.

MLA (9th ed.) Citation

J, Tsuchida, et al. "TRIM37 Expression Is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer." Annals of Surgical Oncology, vol. 33, no. 4, 2026, p. 3263, https://doi.org/10.1245/s10434-025-18764-x.